-- Physicians and employees recognized for their role in this milestone and 
impact made on patient lives

Sirtex Medical ( 
https://c212.net/c/link/?t=0&l=en&o=2500274-1&h=3904953148&u=http%3A%2F%2Fwww.sirtex.com%2F&a=Sirtex+Medical 
), a leading manufacturer of targeted liver cancer therapies, today announced 
delivery of the 100,000th patient dose of SIR-Spheres(R)Y-90 resin 
microspheres, a treatment for patients with liver cancer.* More than 1,000 
healthcare providers and hospital systems across the globe offer this treatment.

Logo - https://mma.prnewswire.com/media/926923/Sirtex_Medical_Logo.jpg

"This milestone would not have been possible without the support of healthcare 
professionals around the world, along with Sirtex's significant investment in 
our Interventional Oncology clinical program. We are also very proud to have 
such dedicated employees who place patients first and are focused on achieving 
excellence in their effort to improve the quality and longevity of patients' 
lives," said Kevin Smith, interim CEO of Sirtex. "However, this is the first of 
many milestones as we continually strive to develop new ways to improve the 
delivery of SIR-Spheres Y-90 resin microspheres and advance the standard of 
care." 

Since the company's creation, Sirtex has been committed to providing 
best-in-class training, support and education to the multi-disciplinary teams 
caring for patients with liver cancer to ensure those who will benefit the most 
from internal radiation therapy have access to treatment and care. Reaching the 
100,000th dose mark is a recognition of efforts worldwide to expand the reach 
of liver-directed treatment with SIR-Spheres Y-90 resin microspheres therapy. 

"Clinical research has long shown the benefits of Selective Internal Radiation 
Therapy (SIRT) with SIR-Spheres Y-90 resin microspheres for patients with 
colorectal liver metastases in the United States. This minimally invasive 
procedure is designed to control liver tumors, while being well-tolerated and 
maintaining patients' quality of life(1,2)," said Dr. Charles Nutting, a 
leading Board-Certified, Fellowship-Trained Interventional Radiologist at 
Minimally Invasive Treatment Specialists in Colorado where he focuses on 
liver-directed cancer therapies. In 2002, Dr. Nutting was the first physician 
to administer SIR-Spheres Y-90 resin microspheres in the U.S. "I'm honored and 
excited to continue a partnership with Sirtex to provide this treatment to U.S. 
patients."

Professor Thomas Helmberger, Chairman of the Department of Radiology, 
Neuroradiology and Nuclear Medicine at Klinikum Bogenhausen in Munich, Germany, 
performed the first SIRT in Europe, the Middle East and Africa with SIR-Spheres 
Y-90 resin microspheres back in 2002. "This is a viable treatment option that I 
encourage patients to consider as part of their plan of care," said Pr. 
Helmberger. "I'm proud to join Sirtex and the medical community in celebrating 
this important milestone."

Professor Guy van Hazel, Medical Oncologist at Mount Hospital in West Perth and 
Clinical Professor of Medicine at the School of Medicine and Pharmacology at 
the University of Western Australia, was part of the early development of 
SIR-Spheres Y-90 resin microspheres. He comments, "This is an important 
treatment option for my patients and a milestone I'm glad to be a part of."

*In the United States, SIR-Spheres Y-90 resin microspheres received Premarket 
Approval (PMA) from the FDA and are indicated for the treatment of 
non-resectable metastatic liver tumors from primary colorectal cancer in 
combination with intrahepatic artery chemotherapy using floxuridine. 
SIR-Spheres Y-90 resin microspheres are approved for the treatment of 
inoperable liver tumors in Australia, the European Union, Argentina, Brazil, 
Canada and several countries in Asia, such as India and Singapore.  

About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin 
microspheres
SIR-Spheres Y-90 resin microspheres is a prescription device for the treatment 
of inoperable liver tumors. It is a minimally invasive treatment that delivers 
high doses of high-energy beta radiation directly to the tumors. SIRT is 
administered to patients by interventional radiologists, who infuse millions of 
radioactive resin microspheres via a catheter into the liver arteries that 
supply blood to the tumors. By using the tumors' blood supply, the microspheres 
selectively target liver tumors with a dose of radiation that is up to 40 times 
higher than conventional radiotherapy, while sparing healthy tissue.

About Sirtex 
Sirtex Medical is a global healthcare business with offices in the U.S., 
Australia, Germany and Singapore, working to improve outcomes in people with 
cancer. Our current lead product is a targeted radiation therapy for liver 
cancer called SIR-Spheres Y-90 resin microspheres. More than 100,000 doses have 
been supplied to treat patients with liver cancer at more than 1,000 medical 
centers in over 40 countries. For more information, visit www.sirtex.com.

SIR-Spheres(R)is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

References
(1) Kennedy A., Cohn M., Coldwell D.M. et al. (2017). "Updated survival 
outcomes and analysis of long-term survivors from the MORE study on safety and 
efficacy of radioembolization in patients with unresectable colorectal cancer 
liver metastases," Journal of Gastrointestinal Oncology. 8(4): 614-624. 
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582033/, accessed 
06/05/2019.
(2) Cosimelli M., Golfieri R., Cagol P.P. et al (2010). "Multi-centre phase II 
clinical trial of yttrium-90 resin microspheres alone in unresectable, 
chemotherapy refractory colorectal liver metastases," British Journal of 
Cancer. 103(3): 324-331. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/20628388, accessed 06/07/2019.

DOC ID: 196-EUA-0619  

SOURCE  Sirtex Medical

CONTACT: Kevin Smith, Phone: +1.781.721.3801, Email: Kevin.Smith@Sirtex.com